Compare MINISO Group Holding Ltd (MNSO) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MINISO Group Holding Ltd vs Sana Biotechnology Inc — how do they compare? MINISO Group Holding Ltd trades at $9.16 (market cap $2.80B), while Sana Biotechnology Inc trades at $3.17 (market cap $947.48M). The key difference: MINISO Group Holding Ltd is far larger — about 3× Sana Biotechnology Inc's market cap, and MINISO Group Holding Ltd pays a 7.22% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| MNSO | SANA | |
|---|---|---|
Market Cap | $2.80B | $947.48M |
Sector | Technology | Health |
52-Week High | $25.31 | $5.92 |
52-Week Low | $9.23 | $2.68 |
Enterprise Value | $3.67B | $860.73M |
Dividend Yield | 7.22% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MNSO trades at $9.36, down 2.09% today, with mixed technical signals showing bearish moving averages but bullish oscillators including oversold RSI levels. Fundamentally, the company reported strong Q1 2026 earnings beat but missed expectations in three of the last four quarters. Revenue grew 22.4% YoY in H1 2026 to RMB 11.5 billion, driven by domestic China performance and store expansion, though overseas markets showed weakness. The company announced a HK$2 billion share repurchase program in June 2026 to support shareholder value.
The stock presents a value opportunity with attractive valuation multiples (P/E 15.25, P/S 0.82) below industry averages, supported by 60% analyst buy ratings and $11.05 consensus price target offering 18% upside. However, inconsistent earnings performance, competitive retail pressures, and overseas execution risks warrant caution. The oversold technical condition suggests potential near-term rebound potential if fundamental improvements materialize.
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
